Skip to main content

Actualités de l’entreprise

Chez Orphalan, nous identifions, développons et donnons accès à des traitements innovants pour les patients atteints de maladies rares.

Dernières actualités, communiqués de presse et vidéos

Filter

Orphalan becomes the first European company to enter in China’s Wilson Disease marketActualités de l’entrepriseCommuniqué de presse

Orphalan becomes the first European company to enter in China’s Wilson Disease market

Strategic partnership with Kyuan Xinhai (Beijing) Medical Products Trade Co., Ltd (“SPH Kyuan Trade”) to transform access to Wilson’s disease treatment for Chinese patients Paris, March 7th 2025 – Orphalan,…
mars 7, 2025
Orphalan announces China NMPA’s approval of its trientine tetrahydrochloride product for the treatment of Wilson diseaseActualités de l’entrepriseCommuniqué de presse

Orphalan announces China NMPA’s approval of its trientine tetrahydrochloride product for the treatment of Wilson disease

Paris, France 18 January, 2024 – Orphalan SA (“Orphalan” or “the Company”), an international orphan drug development and commercialization company, today announces the approval of its trientine tetrahydrochloride product by China’s…
janvier 18, 2024
Tackling rare diseases: Wilson disease patient and millions more like her need helpActualités de l’entreprise

Tackling rare diseases: Wilson disease patient and millions more like her need help

Over the years, I’ve been deeply moved by the stories of many patients, but one particularly stands out. A woman talked about her teenage daughter’s Wilson disease — a rare…
septembre 25, 2023
Why We Should Care About Rare Disease Research – Life Science LeaderActualités de l’entreprise

Why We Should Care About Rare Disease Research – Life Science Leader

Why We Should Care About Rare Disease Research “Access to life-saving or life-enhancing treatments should not be determined by the rarity of the disease; on the contrary, our greater understanding…
mai 9, 2023
Orphalan announces US commercial launch of Cuvrior™ for the treatment of Wilson diseaseCommuniqué de presse

Orphalan announces US commercial launch of Cuvrior™ for the treatment of Wilson disease

– Cuvrior™ now available in the US for the treatment of adult patients with stable Wilson disease who are de-coppered and tolerant to penicillamine – Oral administration offers dosing flexibility…
avril 20, 2023
Podcast: Naseem Amin, Orphalan CEO, discusses Wilson’s Disease and the potential advancements in its treatments on DNA TodayActualités de l’entreprise

Podcast: Naseem Amin, Orphalan CEO, discusses Wilson’s Disease and the potential advancements in its treatments on DNA Today

DNA Today is a multi-award-winning podcast and radio show exploring how genetics impacts our health. Host/Producer Kira Dineen interviews leaders in genetics including genetic counsellors, researchers, physicians, and patient advocates…
février 6, 2023
Orphalan announces publication of results from the CHELATE trial in The Lancet Gastroenterology & HepatologyCommuniqué de presse

Orphalan announces publication of results from the CHELATE trial in The Lancet Gastroenterology & Hepatology

Trial supported Orphalan’s successful application to the United States Food and Drug Administration (FDA) for approval of Cuvrior™ (trientine tetrahydrochloride) for Wilson’s disease Paris, France 30 September, 2022 – Orphalan…
septembre 30, 2022
Orphalan announces enrolment of the first five patients in the International Wilson’s Disease Patient Registry (“iWD Registry”)Communiqué de presse

Orphalan announces enrolment of the first five patients in the International Wilson’s Disease Patient Registry (“iWD Registry”)

World’s first global Wilson’s Registry will provide an international platform for sharing real-world information about Wilson’s disease Registry expected to include 500 individuals affected by this rare disease Paris, France…
août 8, 2022
Dr. Naseem Amin, Chief Executive Officer at Orphalan, discusses the announcement of the FDA approval of Cuvrior™Actualités de l’entrepriseVidéo

Dr. Naseem Amin, Chief Executive Officer at Orphalan, discusses the announcement of the FDA approval of Cuvrior™

Dr. Naseem Amin, Chief Executive Officer at Orphalan, discusses the announcement of the FDA approval of Cuvrior™ in this video: https://www.youtube.com/watch?v=Yu2WsUwtayE
mai 3, 2022
Orphalan announces FDA approval of Cuvrior™ for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamineCommuniqué de presse

Orphalan announces FDA approval of Cuvrior™ for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine

Orphalan announces FDA approval of Cuvrior™ for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine. Paris, France 2 May 2022 – Orphalan…
mai 2, 2022
Orphalan Speaks to Chair of Wilson’s Disease Patient Registry to Celebrate Rare Disease DayCommuniqué de presse

Orphalan Speaks to Chair of Wilson’s Disease Patient Registry to Celebrate Rare Disease Day

Conversation between Omar Kamlin, Senior Medical Director at Orphalan SA and Prof Pramod Mistry, MBBS, PhD, MA, MD, Director of Yale Lysosomal Disease Center and Gaucher Disease Treatment Center at…
février 28, 2022
Orphalan strengthens its management team with two key appointmentsCommuniqué de presse

Orphalan strengthens its management team with two key appointments

Paris, France 1 February 2022 – Orphalan SA, a Company that identifies, develops, and delivers therapies worldwide for orphan diseases, today announces two new appointments to the management team. Tim…
février 1, 2022
En savoir plus

Notre recherche

Nous pensons que les patients du monde entier atteints d’une maladie rare devraient avoir accès à des traitements innovants qui améliorent leur prise en charge et ont un impact positif sur leur vie et celle de leurs proches.

Notre recherche